On November 18, 2020, MedAvail, Inc., a healthcare technology company that embeds pharmacy services directly into clinics and other points of care, announced the completion of its previously announced business combination with MYOS RENS Technology, Inc., an advanced nutrition company focused on improving muscle health. Wilson Sonsini advised MedAvail in the transaction.
Under the terms of the merger agreement, which was previously announced on June 30, 2020, a wholly owned subsidiary of MYOS merged with and into MedAvail, with MedAvail becoming the surviving corporation and a wholly owned subsidiary of MYOS. The combined company will focus on the MedAvail business and its shares will trade on the Nasdaq Capital Market under the new trading symbol “MDVL.” The current MYOS RENS muscle health business will be spun off as a private unaffiliated company.
MedAvail currently deploys its MedCenter solution through two distinct commercialization channels: its SpotRx full-service retail pharmacy platform in the United States and its technologies channel in which it sells its MedCenter kiosk and licenses its proprietary software to large retailers and health systems. SpotRx currently has over 40 clinics deployed across Arizona and California.
The Wilson Sonsini team advising MedAvail includes the following attorneys:
Corporate
Philip Oettinger
Eric Hsu
Ryan Greecher
Brian Currie
Regulatory
Joshua Gruenspecht
David Hoffmeister
Eva Yin
Employee Benefits & Compensation
Michael Klippert, Associate
Litigation
Katherine Henderson
Luke Liss
Mergers & Acquisitions
Ethan Lutske
Ross Tanaka
Please see MedAvail’s press release for more information.